Cellectar Biosciences (NASDAQ:CLRB) will release its earnings data after the market closes on Tuesday, March 13th. Analysts expect Cellectar Biosciences to post earnings of ($0.23) per share for the quarter.
Cellectar Biosciences (CLRB) opened at $1.24 on Friday. The company has a market cap of $18.98, a PE ratio of -1.16 and a beta of 0.75. Cellectar Biosciences has a 1-year low of $1.06 and a 1-year high of $3.07.
A hedge fund recently raised its stake in Cellectar Biosciences stock. Vanguard Group Inc. boosted its position in shares of Cellectar Biosciences Inc (NASDAQ:CLRB) by 31.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 147,208 shares of the biopharmaceutical company’s stock after purchasing an additional 35,482 shares during the period. Vanguard Group Inc. owned about 1.09% of Cellectar Biosciences worth $240,000 at the end of the most recent quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3254354/cellectar-biosciences-clrb-set-to-announce-earnings-on-tuesday.html.
About Cellectar Biosciences
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.